Statins Reduce COVID-19 Severity, Likely by Removing Cholesterol That Virus Uses to Infect | FirstWord Pharma

The clinical study, published September 15, 2020 in American Journal of Cardiology, was led by Lori Daniels, MD, professor and director of the Cardiovascular Intensive Care Unit at UC San Diego Health, and Karen Messer, PhD, professor and chief of the Division of Biostatics and Bioinformatics in the Department of Family Medicine and Public Health. The mechanistic study, published September 18,…

Read the full article here

Source: m.firstwordpharma.com

Categories: Healthcare Professionals, Latest Headlines

Tags: covid19

Tweets with this article

Michael Blaiss, MD

Statins Reduce COVID-19 Severity, Likely by Removing Cholesterol That Virus Uses to Infect | FirstWord Pharma https://t.co/L27jsavg2R

Related Articles

U.S. FDA declines to approve Eli Lilly’s drug to treat eczema

The U.S. Food and Drug Administration (FDA) has declined to approve Eli Lilly’s drug to treat a type of skin disease due to certain findings…

Michael Blaiss, MD October 2, 2023

Protecting children from poor air quality

3 in 4 parents are concerned about the impact of air quality problems on their child’s health. 2 in 3 parents report poor or unhealthy…

Michael Blaiss, MD September 18, 2023

FDA Reviewers Say OTC Decongestant Doesn’t Work

But they acknowledge that taking the only shelf-accessible product off the market raises issues

Michael Blaiss, MD September 8, 2023

Nestlé offloads peanut allergy therapy Palforzia to Stallergenes Greer

Nestlé announced Monday the divestment of its peanut allergy treatment business Palforzia (peanut allergen powder-dnfp) to Stallergenes Greer for an undisclosed sum. Nestlé kicked off…

Michael Blaiss, MD September 4, 2023

AstraZeneca Halts Phase II Asthma Trial Due to Safety Findings in Toxicology Study | BioSpace

Pieris Pharmaceuticals announced partner AstraZeneca’s decision to discontinue clinical studies of elarekibep, an inhaled IL-4 receptor alpha inhibitor, based on a non-clinical toxicology study.

Michael Blaiss, MD June 22, 2023

FirstWord

Michael Blaiss, MD May 23, 2023

‘Stunning’ change to United’s colonoscopy coverage roils physicians and patients

For patients who have undiagnosed cancer, a months-long delay due to new prior authorization requirements for colonoscopies could be disastrous.

Michael Blaiss, MD May 15, 2023

Dupilumab not linked to short-term cancer development in patients with atopic dermatitis

Patients with atopic dermatitis treated with dupilumab did not experience any significantly increased risk for a primary or recurrent malignancy, according to a study published…

Michael Blaiss, MD April 4, 2023

FDA approves leniolisib for activated phosphoinositide 3-kinase delta syndrome

The FDA approved leniolisib as the first treatment for activated phosphoinositide 3-kinase delta syndrome in adults and pediatric patients 12 years of age and older.

Michael Blaiss, MD March 30, 2023

FirstWord

Michael Blaiss, MD March 24, 2023